NewAmsterdam Pharma (NASDAQ:NAMS) Director James N. Topper Buys 1,135 Shares

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) Director James N. Topper acquired 1,135 shares of the firm's stock in a transaction that occurred on Wednesday, March 26th. The shares were bought at an average cost of $22.49 per share, for a total transaction of $25,526.15. Following the acquisition, the director now owns 3,013,569 shares of the company's stock, valued at $67,775,166.81. This represents a 0.04 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.

NewAmsterdam Pharma Price Performance

NAMS traded down $2.09 during trading on Tuesday, hitting $18.38. The company's stock had a trading volume of 2,585,205 shares, compared to its average volume of 545,463. NewAmsterdam Pharma has a twelve month low of $15.19 and a twelve month high of $27.29. The stock has a market cap of $2.02 billion, a PE ratio of -7.07 and a beta of -0.04. The firm's 50 day moving average price is $21.50 and its 200-day moving average price is $21.32.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The company had revenue of $12.77 million during the quarter, compared to analysts' expectations of $3.30 million. Equities analysts anticipate that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

Remove Ads

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Geode Capital Management LLC increased its position in NewAmsterdam Pharma by 1.6% during the third quarter. Geode Capital Management LLC now owns 86,322 shares of the company's stock worth $1,433,000 after purchasing an additional 1,399 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of NewAmsterdam Pharma during the 4th quarter valued at $50,000. National Bank of Canada FI acquired a new stake in shares of NewAmsterdam Pharma during the 4th quarter worth $51,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of NewAmsterdam Pharma in the 4th quarter worth $80,000. Finally, California State Teachers Retirement System boosted its holdings in NewAmsterdam Pharma by 23.5% in the fourth quarter. California State Teachers Retirement System now owns 19,404 shares of the company's stock valued at $499,000 after acquiring an additional 3,694 shares during the last quarter. 89.89% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently weighed in on NAMS. HC Wainwright restated a "buy" rating and issued a $48.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. UBS Group set a $41.00 price target on shares of NewAmsterdam Pharma in a report on Monday, March 3rd. Royal Bank of Canada reissued an "outperform" rating and set a $40.00 price objective on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. Needham & Company LLC reduced their target price on NewAmsterdam Pharma from $46.00 to $42.00 and set a "buy" rating on the stock in a research note on Thursday, February 27th. Finally, Scotiabank boosted their price target on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a report on Thursday, February 27th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $43.33.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.